295 related articles for article (PubMed ID: 21083802)
1. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Kim BK; Ahn SH; Seong JS; Park JY; Kim DY; Kim JK; Lee DY; Lee KH; Han KH
Liver Int; 2011 Mar; 31(3):369-76. PubMed ID: 21083802
[TBL] [Abstract][Full Text] [Related]
2. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma.
Lee MH; Kim SU; Kim DY; Ahn SH; Choi EH; Lee KH; Lee DY; Seong J; Han KH; Chon CY; Park JY
J Gastroenterol Hepatol; 2012 Feb; 27(2):313-22. PubMed ID: 21793906
[TBL] [Abstract][Full Text] [Related]
3. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma.
Kim BK; Kang WJ; Kim JK; Seong J; Park JY; Kim DY; Ahn SH; Lee DY; Lee KH; Lee JD; Han KH
Cancer; 2011 Oct; 117(20):4779-87. PubMed ID: 21469082
[TBL] [Abstract][Full Text] [Related]
4. Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Jeong Y; Yoon SM; Han S; Shim JH; Kim KM; Lim YS; Lee HC; Kim SY; Park JH; Lee SW; Ahn SD; Choi EK; Kim JH
PLoS One; 2015; 10(8):e0135298. PubMed ID: 26252472
[TBL] [Abstract][Full Text] [Related]
5. Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy.
Lee HS; Choi GH; Choi JS; Kim KS; Han KH; Seong J; Ahn SH; Kim DY; Park JY; Kim SU; Kim BK
Ann Surg Oncol; 2014 Oct; 21(11):3646-53. PubMed ID: 24916746
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis.
Park MS; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Chon CY; Seong J
Cancer Chemother Pharmacol; 2013 Jan; 71(1):165-73. PubMed ID: 23079897
[TBL] [Abstract][Full Text] [Related]
7. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
[TBL] [Abstract][Full Text] [Related]
8. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.
Saeki I; Yamasaki T; Tanabe N; Iwamoto T; Matsumoto T; Urata Y; Hidaka I; Ishikawa T; Takami T; Yamamoto N; Uchida K; Terai S; Sakaida I
PLoS One; 2015; 10(5):e0126649. PubMed ID: 25992784
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study.
Kim JK; Kim JW; Lee IJ; Joo SM; Lee KH; Cho ES; Yu JS; Jeon TJ; Kim Y; Lee JI; Lee KS
Radiat Oncol; 2017 Aug; 12(1):133. PubMed ID: 28810886
[TBL] [Abstract][Full Text] [Related]
10. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival.
Riaz A; Ryu RK; Kulik LM; Mulcahy MF; Lewandowski RJ; Minocha J; Ibrahim SM; Sato KT; Baker T; Miller FH; Newman S; Omary R; Abecassis M; Benson AB; Salem R
J Clin Oncol; 2009 Dec; 27(34):5734-42. PubMed ID: 19805671
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers.
Miyaki D; Kawaoka T; Aikata H; Kan H; Fujino H; Fukuhara T; Kobayashi T; Naeshiro N; Honda Y; Tsuge M; Hiramatsu A; Imamura M; Hyogo H; Kawakami Y; Yoshimatsu R; Yamagami T; Awai K; Chayama K
J Gastroenterol Hepatol; 2015 Apr; 30(4):726-32. PubMed ID: 25311578
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.
Onishi H; Nouso K; Nakamura S; Katsui K; Wada N; Morimoto Y; Miyahara K; Takeuchi Y; Kuwaki K; Yasunaka T; Miyake Y; Shiraha H; Takaki A; Kobayashi Y; Sakaguchi K; Kanazawa S; Yamamoto K
Hepatol Int; 2015 Jan; 9(1):105-12. PubMed ID: 25788384
[TBL] [Abstract][Full Text] [Related]
14. Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy.
Han DH; Joo DJ; Kim MS; Choi GH; Choi JS; Park YN; Seong J; Han KH; Kim SI
Yonsei Med J; 2016 Sep; 57(5):1276-81. PubMed ID: 27401662
[TBL] [Abstract][Full Text] [Related]
15. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
[TBL] [Abstract][Full Text] [Related]
17. Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma.
Cha H; Yoon HI; Lee IJ; Koom WS; Han KH; Seong J
J Radiat Res; 2013 Nov; 54(6):1069-77. PubMed ID: 23633620
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Outcome of Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma by the Combination of RECIST and Tumor Markers.
Hatooka M; Kawaoka T; Aikata H; Honda F; Nakamura Y; Nakano N; Morio K; Fukuhara T; Kobayashi T; Nagaoki Y; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Chayama K
Hiroshima J Med Sci; 2016 Sep; 65(2):25-33. PubMed ID: 29989682
[TBL] [Abstract][Full Text] [Related]
19. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy.
Chan SL; Mo FK; Johnson PJ; Hui EP; Ma BB; Ho WM; Lam KC; Chan AT; Mok TS; Yeo W
J Clin Oncol; 2009 Jan; 27(3):446-52. PubMed ID: 19064965
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K
Oncology; 2018; 94(4):215-222. PubMed ID: 29428943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
